logo
Share SHARE
FONT-SIZE Plus   Neg

Bayer's Stivarga Gets FDA Approval For Treatment Of Gastrointestinal Tract Tumor

Bayer Healthcare, a part of German drug maker Bayer AG (BAYRY.PK,BAYZF.PK,BYR.L), announced Monday that the U.S. Food and Drug Administration has approved its Stivarga tablets as a treatment for one of the most common tumors of the gastrointestinal tract.

The drug is indicated for patients with locally advanced, unresectable or metastatic gastrointestinal stromal tumor (GIST) who have been previously treated with imatinib mesylate and sunitinib malate.

Stivarga or regorafenib, is an oral multi-kinase inhibitor that targets oncogenesis, tumor angiogenesis and maintenance of the tumor microenvironment signaling by inhibiting multiple protein kinases.

Regorafenib is a compound developed by Bayer Healthcare and jointly promoted by Bayer and California-based Onyx Pharmaceuticals, Inc. (ONXX) in the U.S. as per a 2011 deal, under which Onyx will receive a royalty on all global net sales of regorafenib in oncology.

Bayer's potential blockbuster cancer Stivarga was earlier approved by the FDA in late September for the treatment of patients with metastatic colorectal cancer (mCRC).

"The second approval for Bayer's Stivarga in the U.S. reveals the drug's potential to fulfill serious unmet medical needs for patients with cancer who require new medicines that continue to slow the progression of their disease," the company said in a statement.

The FDA approval is based on results from the pivotal late stage study that demonstrated significant improvement in progression-free survival (PFS) compared to placebo in patients with GIST whose disease had progressed after treatment with imatinib mesylate and sunitinib malate.

Stivarga was developed under the Fast Track program and received priority review designations for metastatic or unresectable GIST and mCRC from the FDA in late June 2012 after the drug met its primary goals in late-stage study of patients with GIST in early June.

These designations are granted by the FDA to expedite the development and review of drugs to treat serious diseases and fulfill an unmet medical need, and are given to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists.

In December 2012, Bayer submitted a filing to the Ministry of Health, Labour and Welfare or MHLW, in Japan for regorafenib for the treatment of GIST. An NDA for regorafenib for the treatment of advanced CRC filed in July 2012 with the MHLW in Japan was also granted priority review in early September.

GIST is the most common form of sarcoma arising from the muscle wall of the gastrointestinal tract. GIST represents a life-threatening malignancy if the disease has spread to other parts of the body (metastasized) or is unable to be surgically removed with curative intent. The incidence of GIST is estimated to be 11 to 20 patients per million per year.

On Frankfurt's Xetra, Bayer shares closed Monday's regular trading at 73.75 euros, up 0.75 euros or 1.03% on a volume of 2.92 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
Canada based Maple Leaf Foods Inc. Wednesday said it has reached a definitive agreement with Brynwood Partner VI L.P. for the acquisition of Lightlife Foods Inc. The deal would be worth $140 million plus other costs. Light is a brand in U.S. for refrigerated plant based protein foods. A hedge fund is an alternative investment fund that uses pooled funds from accredited individuals or institutional investors and invests these funds in different assets with a goal of generating high returns. Hedge funds are generally accessible only to accredited or qualified investors. They cannot... Off-price retailer TJX Companies, Inc. reported a nearly 2 percent increase in profit for the fourth quarter from last year, reflecting higher sales and customer traffic. Both revenue and earnings per share for the quarter beat analysts' expectations. The company forecast earnings for the first quarter below the Street estimates and projects fiscal 2018 earnings above their expectations.
comments powered by Disqus
Follow RTT